Search results for: ""

Showing 111-120 of 454 results

Website - Helsinn will attend at ASCO 2017 10/01/2017 11:15am

The "2017 ASCO Annual Meeting -Making a Difference in Cancer Care" will take place in Chicago, Illinois, on June 2-6 2017

Website - ESMO 2017 in Madrid 10/01/2017 10:23am

Helsinn will be present in Madrid, Spain on 8-12 September 2017, at the ESMO 2017 congress. You can meet us at booth #65.

News - Helsinn Group Launches “Helsinn Cares” Patient Support Services 13/02/2017 3:35pm

Patient Assistance Program and Voucher Program will support both insured and uninsured patients in the United States get access to medicines that can ease the burden of chemotherapy side effects Akynzeo® to be first Helsinn marketed product to be provided through “Helsinn Cares” program in the United States

News - Mundipharma and Helsinn Group Expand Exclusive Licensing and Distribution Agreements for Leading Anti-emetic Products in Middle East, Africa, Latin America and Indonesia 14/02/2017 9:19am

Anti-emetic products covered under expanded agreements include ALOXI® and AKYNZEO®. Both are prophylactic agents for the treatment of chemotherapy induced nausea and vomiting Exclusive agreements cover marketing, sales and distribution.

Website - DCAT 2017 - New York City 02/02/2017 1:47pm

DCAT 2017 will take place in New York City from March 20th to March 23rd 2017 and Helsinn will be there.

Website - CPhI Japan-2017 01/02/2017 12:00am

CPhI Japan is the largest japanese pharmaceutical exhibition

News - Helsinn Provides Grant for ESMO’s Preceptorship Course on Supportive and Palliative Care 15/02/2017 8:00am

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, announces that the Group has provided a grant to the European Society for Medical Oncology (“ESMO”) for a preceptorship event dedicated to supportive and palliative care for physicians.

News - Helsinn Advanced Synthesis announces investment - Helsinn Advanced Synthesis annuncia investimenti 21/02/2017 3:37pm

Significant new investment totaling CHF15m,supported by Canton of Ticino, prompted by expanding demand for anticancer therapeutics Importanti nuovi investimenti per un totale di 15 milioni di franchi, con il supporto del Canton Ticino, in seguito alla crescente domanda di terapie antitumorali.